March 2025
1. VERSIJPT J, Paemeleire K, Reuter U, MaassenVanDenBrink A, et al
   Calcitonin gene-related peptide-targeted therapy in migraine: current role and future perspectives.
   Lancet. 2025;405:1014-1026.
   

   >> Share

   
   November 2023
2. DODICK DW, Goadsby PJ, Schwedt TJ, Lipton RB, et al
   Ubrogepant for the treatment of migraine attacks during the prodrome: a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in the USA.
   Lancet. 2023 Nov 15:S0140-6736(23)01683-5. doi: 10.1016/S0140-6736(23)01683.
   

   >> Share

   
   July 2023
3. POZO-ROSICH P, Ailani J, Ashina M, Goadsby PJ, et al
   Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial.
   Lancet. 2023 Jul 26:S0140-6736(23)01049-8. doi: 10.1016/S0140-6736(23)01049.
   

   >> Share

   
   
4. HAANES KA, Edvinsson L
   Atogepant, the first oral preventive treatment for chronic migraine.
   Lancet. 2023 Jul 26:S0140-6736(23)01462-9. doi: 10.1016/S0140-6736(23)01462.
   

   >> Share

   
   

Free Medical Abstracts
Privacy Policy
Sponsors
Share